Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Merck Passes Huntington’s RNAi Program To Targeted Genetics

This article was originally published in The Pink Sheet Daily

Executive Summary

Sirna division’s early-stage targets are of lesser interest to the pharma firm, analyst tells “The Pink Sheet” DAILY.

You may also be interested in...



Clinical Stage Biotechs For Sale?

The oversized price tag attached to the recent acquisition of Pharmasset by Gilead has caused many to wonder how the take-out fits into historical patterns – or if it’s as big an outlier as it seems.

Prestwick’s Xenazine For Huntington’s Chorea Gets Positive Vote From FDA Panel

FDA’s Peripheral and CNS Drug advisory panel votes unanimously that adverse events associated with the Huntington’s disease treatment do not trump the drug’s proven efficacy.

Amarin Plans Additional Phase III Trial For Miraxion To Support Huntington's NDA

London firm aims to substantiate the effectiveness of the neuroprotector in a genetic subgroup of Huntington's patients.

Related Content

Topics

UsernamePublicRestriction

Register

PS067703

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel